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Abstract
Background: Cancer stem cells (CSCs) are regarded as the cause of tumor formation and recurrence. The isolation
and identification of CSCs could help to develop novel therapeutic strategies specifically targeting CSCs.
Methods: Human hepatoma cell lines were plated in stem cell conditioned culture system allowed for sphere
forming. To evaluate the stemness characteristics of spheres, the self-renewal, proliferation, chemoresistance,
tumorigenicity of the PLC/PRF/5 sphere-forming cells, and the expression levels of stem cell related proteins in the
PLC/PRF/5 sphere-forming cells were assessed, comparing with the parental cells. The stem cell RT-PCR array was
performed to further explore the biological properties of liver CSCs.
Results: The PLC/PRF/5, MHCC97H and HepG2 cells could form clonal nonadherent 3-D spheres and be serially
passaged. The PLC/PRF/5 sphere-forming cells possessed a key criteria that define CSCs: persistent self-renewal,
extensive proliferation, drug resistance, overexpression of liver CSCs related proteins (Oct3/4, OV6, EpCAM, CD133
and CD44). Even 500 sphere-forming cells were able to form tumors in NOD/SCID mice, and the tumor initiating
capability was not decreased when spheres were passaged. Besides, downstream proteins DTX1 and Ep300 of the
CSL (CBF1 in humans, Suppressor of hairless in Drosophila and LAG1 in C. elegans) -independent Notch signaling
pathway were highly expressed in the spheres, and a gamma-secretase inhibitor MRK003 could significantly inhibit
the sphere formation ability.
Conclusions: Nonadherent tumor spheres from hepatoma cell lines cultured in stem cell conditioned medium
possess liver CSC properties, and the CSL-independent Notch signaling pathway may play a role in liver CSCs.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third leading cause of cancer death
worldwide [1,2]. Its overall incidence remains alarmingly
high in the developing countries and is steadily rising
across most of the developed countries [1-3]. Although
the cytologic pathogenesis of HCC remains unclear, it
has been proposed that only a small fraction of cancer
cells with stem cell properties, named cancer stem cells
(CSCs), is responsible for the initiation, progression,
local and distant recurrence/metastasis of HCC, also for
the failure of chemo- and radiotherapy. The clinical cor-
ollary of this hypothesis has been extended to proposals
to treat cancer by targeting the putative liver CSCs.
Numerous attempts have been made to identify cells
with stem cell properties in established HCC cell lines.
Different research groups have reported that liver CSC
fractions could be successfully enriched by some cell sur-
face phenotypes, specifically CD133, CD90, CD44,
epithelial cell adhesion molecule (EpCAM), OV6 and
CD13 [4-9]. Nevertheless, these proteins, which are
involved in embryonic and somatic stem cell function,
embryonic development, hepatocyte membrane transport
and growth control, have been demonstrated a relative
lack of sensitivity and specificity for identifying liver
CSCs [10-12]. So far, no markers for putative liver CSCs
have yet been generally accepted, and further study is
needed to explore the isolation method for liver CSCs.
A major advance in adult stem cell research was
achieved in 1996 when it was discovered that the undif-
ferentiated multipotent neural cells could be grown and
maintained in suspension using the neurosphere assay
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stem cells was instrumental in the study of adult stem
cells including the nerve, prostate and mammary stem
cells [14-17]. Recently, as a functional approach, sphere
formation is particularly useful to enrich the potential
CSC subpopulations when the specific CSC makers have
not been defined as the case for most CSCs [18-25].
However, there have been few reports for sphere culture
in liver cancer. Therefore, the present study intends to
establish an alternate approach to isolate, identify and
characterize liver cancer cell subsets with CSC properties.
Methods
Cell lines and sphere culture
Human hepatoma cell lines, PLC/PRF/5 and HepG2, were
obtained from the Cell Bank of Chinese Academy of
Sciences (Shanghai, China). MHCC97H was obtained
from the Liver Cancer Institute, Zhongshan Hospital,
Fudan University (Shanghai, China). All of the cells were
maintained as a monolayer in high glucose DMEM with
10% fetal bovine serum (FBS), 100 IU/ml penicillin G and
100 μg/ml streptomycin at 37°C in a humidified 5% CO2
incubator. Cells were collected and washed to remove
serum, then suspended in serum-free DMEM/F12 supple-
mented with 100 IU/ml penicillin, 100 μg/ml streptomy-
cin, 20 ng/ml human recombinant epidermal growth
factor (hrEGF), 10 ng/ml human recombinant basic fibro-
blast growth factor (hrbFGF), 2% B27 supplement without
vitamin A, 1% N2 supplement (Invitrogen, Carlsbad, CA,
USA). The cells were subsequently cultured in ultra low
attachment 6-well plates (Corning Inc., Corning, NY,
USA) at a density of no more than 5,000 cells/well.
Sphere passage and sphere formation assay
The spheres were collected by gentle centrifugation, then
dissociated with trypsin-EDTA and mechanically dis-
rupted with a pipette. The resulting single cells were then
centrifuged to remove the enzyme and re-suspended in
serum-free medium allowed to re-form spheres. The
spheres should be passaged every 5-8 days before they
reached a diameter of 100 μm. The dissociated single
sphere-forming cells were also diluted to a density of
500 cells/ml. Then, the 2 μl/well diluted cell suspension
was plated to ultra low attachment 96-well plate (Corning
I n c . ,C o r n i n g ,N Y ,U S A ) ,a n d1 5 0μl of serum-free med-
ium was added. The wells with only one cell were marked
and observed everyday.
Colony formation assay
The PLC/PRF/5 spheres were enzymatically dissociated
as described above. Trypan blue staining was used to
determine cell viability, and more than 95% of cells with
viability were acceptable for the following experiments.
The single cells were seeded in DMEM with 10% FBS at
a density of 2000 cells/well on 6-well plates that were
pre-coated with Matrigel (BD Biosciences, San Jose, CA,
USA). After 7 days, the colony formation ability was
assessed by counting the number of colonies (> 70 cells)
under a microscope after crystal violet staining (Sigma-
Aldrich, St. Louis, MO, USA). Representative views were
photographed. The parental cells were plated at the
same density as the control.
Chemotherapy sensitivity assays
The sensitivity of the PLC/PRF/5 parental and sphere-
forming cells to chemotherapeutic drugs was measured
by MTT assay. Briefly, cells were seeded in 96-well
plates that were precoated with Matrigel, and various
concentrations of cisplatin (Sigma-Aldrich) were added
at the beginning, co-incubated for 12 h or 24 h. After
changing to fresh medium without cisplatin, cells were
cultured for another 72 h. The MTT reagent (Sigma-
Aldrich) was then added to each well according to the
manufacturer’s instructions. Absorbance was measured
at 490 nm.
Immunofluorescent staining
Cells were fixed in 4% paraformaldehyde and blocked
with normal goat serum. The primary antibodies,
including mouse anti-human OV6 (R&D Systems Inc.,
Minneapolis, MN, USA), mouse anti-human CD133 and
rabbit anti-human CD44 (Santa Cruz Biotechnology,
Inc. Santa Cruz, CA. USA) were added and incubated
o v e r n i g h ta t4 ° C .A f t e rw a s h i n g3t i m e sw i t hP B S ,t h e
goat anti-mouse IgG and goat anti-rabbit secondary
antibodies conjugated with Cy3, FITC or TRITC (Jack-
son ImmunoResearch Laboratories Inc., West Grove,
PA, USA) were added and incubated at room tempera-
ture for 1 h. Cells were then counterstained with DAPI
(Sigma-Aldrich) and the images were captured using an
Olympus-IX71 fluorescent microscope (Olympus Inc.,
Center Valley, PA, USA).
In vivo tumorigenicity experiments
All mice were cared for in accordance with institutional
guidelines. The PLC/PRF/5 parental and the third, sixth
and ninth passages of sphere-forming cells were used in
tumorigenicity experiments. Trypan blue staining was
used to assess cell viability, and various numbers of
viable single cells were subcutaneously injected into 5-
week-old NOD/SCID male mice (Shanghai Laboratory
Animal Center, Chinese Academy of Sciences, Shanghai,
China) in serum-free DMEM/Matrigel (1:1) using 100 μl
microsyringe. Mice were killed at 8 weeks after cell
injection, then the tumors were harvested for further
examination.
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Human Stem Cell RT
2 Profiler™ PCR Array (PAHS-
405A, SABioscience, USA) was done according to the
manufacturer’s instructions. Briefly, RNA samples from
both the PLC/PRF/5 parental cells (as control) and the
tertiary passage spheres were prepared. After removal of
contaminating DNA from RNA preparations, total RNA
samples were cleaned up and the resulting RNA were
assessed for both yield and quality. After the first strand
cDNA was synthesized, real-time PCR was performed.
The data were analyzed using the ΔΔCt method.
Western blotting analysis
Quantified protein lysates were resolved on SDS-PAGE
gels, transferred onto a polyvinylidene difluoride mem-
brane (Millipore, Billerica, MA, USA), and immuno-
blotted with the primary antibodies against EpCAM,
CD133, activated Notch1, Ep300 (Abcam, Cambridge,
M A ,U S A ) ,D T X 1 ,O c t 3 / 4( S a n t aC r u z ,C A ,U S A ) ,o r
OV6, CD44 (R&D Systems Inc., MN, USA), followed by
incubation with the horseradish peroxidase-conjugated
secondary antibody. The blots were visualized using a
supersignal west femto maximum sensitivity substrate
kit (Pierce, Waltham, MA, USA). GAPDH was used as a
loading control.
Statistical analysis
All values in the figures and text were showed as means ±
SD. Statistical analyses were performed using the SPSS
statistical software package (SPSS/PC+, SPSS Inc., Chi-
cago, IL, USA). Any significant differences among mean
values were evaluated by the student’s t test. A two-sided
P < 0.05 was accepted as significant.
Results
Hepatoma cells could form anchorage-independent, self-
renewing spheres
The hepatoma cells were plated in stem cell conditioned
culture medium in 6-well plates at a density of 5,000
cells/well which allowed for the formation of colonies
separated from each other. In this condition, cells grew
as nonadherent, three-dimensional sphere clusters, called
spheres. Figure 1A showed anchorage-independent
spheres formed by the HepG2, MHCC97H and PLC/
PRF/5 cells. After 5 to 8 days, when the spheres grew to
70 to 100 μm in diameter, they were passaged and the
Figure 1 Hepatoma cells formed the anchorage-independent, self-renewing spheres. (A) Hepatoma cell lines, including HepG2, MHCC97H
and PLC/PRF/5, could form the anchorage-independent 3-D spheres in stem cell conditioned culture medium (200×). (B) Generation of a sphere
from a single PLC/PRF/5 cell. The propagation of a single cell cultured in a 96-well dish was recorded at day 1, 3, 5, 7, 9 and 13, separately
(400×).
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spheres again. A key property of all normal and cancer
stem cells is their unique ability to self-renew. One of the
methods to determine the self-renewal capacity of
sphere-forming cells is to test their capability of serial
passage. The PLC/PRF/5, HepG2 and MHCC97H
spheres had been serially passaged for more than 12 gen-
erations, indicating their self-renewal capability in vitro.
To corroborate the finding that a sphere could be gen-
erated from a single cell, one PLC/PRF/5 cell per well
was plated to a 96-well plate and the wells with one cell
were visualized everyday. Figure 1B showed the process
of single PLC/PRF/5 cell forming a sphere.
Sphere-forming cells proliferate extensively in vitro
We compared the proliferative ability of the tertiary pas-
sage PLC/PRF/5 spheres and its parental cell line using
clonogenicity assay. Both of them were adherently plated
and were alive, but were unable to form comparable
colonies. The sphere-forming cells proliferated signifi-
cantly faster and induced bigger and greater numbers of
tumor colonies than the parental cells. Based on count-
ing the number of colonies per 2,000 seeded cells, it was
175.67 ± 30.07/381.00 ± 61.02 (P = 0.006) for the paren-
tal/sphere-forming PLC/PRF/5 cells (Figure 2A). The
sphere-forming cells were capable of extensive prolifera-
tion, indicating that the sphere-forming cells could play
an important role in the maintenance of tumor growth.
Sphere-forming cells possess the ability of resistance to
conventional chemotherapy in vitro
HCC cells are commonly resilient to chemotherapy. It is
speculated that cancer stem or progenitor cells in HCC
are more resistant to conventional chemotherapy contri-
buting to recurrence. To examine whether the self-
renewing sphere-forming cells possess a hypothesized
CSC chemoresistant property, the sensitivity of the
PLC/PRF/5 parental cells versus the tertiary passage
sphere-forming cells to cisplatin was assessed. The sur-
vival rates of sphere-forming cells were higher under the
treatment of 3 μg/ml, 5 μg/ml and 9 μg/ml cisplatin for
12 h, being 1.4-fold, 1.9-fold, 1.8-fold, respectively, com-
pared with the parental PLC/PRF/5 cells (P <0 . 0 1 ) ,
whereas, under the treatment for 24 h, the relative sur-
vival rates were increased to 1.5-fold, 2.1-fold and 2.3-
fold respectively (Figure 2B, P < 0.01).
We also tested the sensitivity of sphere-forming cells
to other 4 drugs in addition to cisplatin. The PLC/PRF/
5 sphere-forming cells exhibited general resistance to 5-
Fu, gemcitabine, mitomycin and sorafenib in the treat-
ment of 36 h. Compared with the PLC/PRF/5 parental
cells, the survival rates of PLC/PRF/5 sphere-forming
cells were higher under 200 μmol/L, 400 μmol/L of 5-
Fu (1.60-fold, 1.98-fold respectively, P < 0.01); 5 mmol/
L, 10 mmol/L of gemcitabine (1.99-fold, 2.49-fold
respectively, P <0 . 0 1 ) ;0 . 5μmol/L, 1.0 μmol/L of mito-
mycin (1.24-fold, 2.33-fold respectively, P <0 . 0 1 ) ;a n d6
μmol/L, 12 μmol/L of serafenib (2.07-fold, 15.21-fold
respectively, P < 0.01). The results support a role for
these sphere-forming cells in HCC chemoresistance,
which may explain why current therapies fail to eradi-
cate progenitors and prevent tumor re-growth.
Sphere-forming cells exhibit high tumorigenicity in vivo
To confirm that the sphere-forming cells exhibit greater
tumor initiating capability, NOD/SCID mice were trans-
planted with varying amounts of the PLC/PRF/5 sphere-
forming cells ranging from the amount that is unable to
initiate tumor growth to the amount that always initiates
tumor formation. The PLC/PRF/5 parental cells were
operated as controls. As few as 500 sphere-forming cells
were sufficient for tumor development, whereas, at least
2×1 0
5 parental cells were necessary to consistently
g e n e r a t eat u m o ri nt h es a m em o d e l ,a n dn o tt om e n -
tion, requiring a longer period of time (Table 1 Figure
3). The tumor nodules formed by the PLC/PRF/5
sphere-forming cells displayed similar histology to that
by the parental cells. To inspect whether the tumor
initiating capability could be decreased as the spheres
were passaged, we also compared the tumorigenicity of
different generations of spheres. The results showed that
both the tumor initiating capability and phenotypic
appearance were similar for the 3th, 6th and 9th genera-
tions of sphere-forming cells (Table 1). The tumorigenic
efficacies of three cell lines HepG2, PLC/PRF/5 and
MHCC97H were also compared in nude mice (Addi-
tional file 1 Figure S1). The results suggested that the
tumorigenic efficacies of sphere-forming cancer cells
were enhanced compared with the parental cells, and
the volumes of tumors were positively correlated with
malignant grade of the cell lines (malignant grade
HepG2 < PLC/PRF/5 < MHCC97H). Interestingly, the
HepG2 parental cells at 10
6 cells/mouse could not form
visible xenografts (0/5), but the HepG2 sphere-forming
cells at 10
6 cells/mouse could form xenograft tumors in
the same period of 30 days.
Sphere-forming cells overexpress liver CSC related
proteins and the CSL-independent Notch signaling
pathway might play a role in liver CSCs
To date, anti-OV6, a monoclonal antibody raised against
cells isolated from carcinogen treated rat liver [26],
remains the best available marker of hepatic stem cells
[27], even though it also reacts with bile duct epithelium
in rats and humans [28]. Besides, Yang et al reported
that the OV6
+ liver cancer cells may represent a potential
stem/progenitor-like cell population [8]. Immunofluores-
cent staining for OV6 showed that most of the PLC/PRF/
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Page 4 of 11Figure 2 Sphere-forming cells proliferated extensively and possessed resistance ability to conventional chemotherapeutics in vitro.
(A) Comparison of in vitro clonogenecity of the PLC/PRF/5 parental cells and sphere-forming cells. Cells were plated at a density of 2,000 cells/
well in 6-well plates and cultured for 1 week. At the end, cells were stained with crystal violet, photographed, and analyzed for their proliferation
efficiency. Each experiment was performed in triplicate, and the representative examples were shown (Columns, mean; bars, SD; *, P < 0.01).
(B) The PLC/PRF/5 sphere-forming cells showed a drug resistance phenotype. The parental cells and sphere-forming cells were treated with
cisplatin at the beginning of plating for 12 h or 24 h and 5-Fu, gemcitabine, mitomycin and sorafenib for 36 h. Cell survival was determined by
MTT assay (**, P < 0.01).
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Then, liver CSCs related proteins, including Oct3/4,
OV6, EpCAM, CD133 and CD44 were examined by
Western blotting. The results displayed that all of them
were significantly increased as compared to the parental
cells (Figure 4B), denoting that the PLC/PRF/5 spheres
possess stem cell-like properties. We also compared the
expression of candidate CSC markers CD133 and CD44
between the parental and sphere-forming cells of HepG2
and MHCC97H by immunofluorescent labelling. It was
found that CD44 expression was obviously enriched in
HepG2 and MHCC97H sphere-forming cells compared
with their parental cells (Additional file 2, Figure S2).
To further explore the biological properties of liver
CSCs, the Stem Cell RT
2 Profiler™ PCR array was per-
formed. This array profiles the expression of 84 genes
related to the identification, growth and differentiation of
stem cells. Among the significantly distinguishing genes,
we noted the DTX1 and Ep300, CSL-independent Notch
signaling pathway related genes, were 4.24-fold and 2.36-
fold, respectively, more abundant in the spheres than
those in the control. Consistent results were confirmed
by Western blotting (Figure 5A). To determine the role
of CSL-independent Notch signals, blocking Notch path-
way was performed by a gamma-secretase inhibitor
MRK003. The secondary dissociated PLC/PRF/5 sphere-
forming cells were treated with 10 μM MRK003 or
DMSO control for 7 days. The inactivation of Notch1
and down-regulations of downstream target genes DTX1
and Ep300 were confirmed by Western blotting (Figure
5B). The sphere formation ability of the MRK003-treated
groups was significantly inhibited in comparison to the
DMSO-treated controls (Figure 5C). The results indi-
cated that the CSL-independent Notch signaling pathway
might play an important role in liver CSCs and MRK003
could partly eliminate the stem-like cells.
Discussion
There are two classical models of carcinogenesis [29,30].
One is the stochastic model, which is based on the belief
that most of tumor cells are capable of extensive prolifera-
tion and contribute substantially to tumor maintenance;
carcinogenesis could results from the random mutations
and the subsequent clonal selections. The other is the
hierarchical model, which is based on the belief that there
are hierarchical differences among tumor cells, and only a
small number of specific cells capable of extensive prolif-
eration can contribute to carcinogenesis. The discovery of
CSCs in solid tumors strongly supports the hierarchical
model. The CSC hypothesis considers that CSCs subsets
are located in the top of the hierarchical structure of
tumor cells and directly affect the organization and con-
struction of lower hierarchical cells. Therefore, the identi-
fication of tumorigenic liver CSCs could provide new
insight into the HCC tumorigenic process and possibly
bear great therapeutic implications.
Table 1 Tumorigenicity experiments of PLC/PRF/5 sphere-forming cells and parental cells in NOD/SCID mice
Cell type Cell numbers injected Tumor incidence
† Latency(days)
‡








































†The number of tumors detected/number of injections.
‡Approximate number of days from tumor cell injection to appearance of a tumor.
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involve two types of methods: one is based on the sorting
of side population (SP) cells that can exclude the hoechst
33342 dye [31]. However, Hoechst 33342 is cytotoxic;
consequently, SP cells are protected by their membrane
transport properties, whereas unprotected non-SP cells
suffer toxicity and are unable to grow. Thus the differing
tumor-initiation abilities of SP and non-SP cells are most
likely due to an artifact of Hoechst 33342 toxicity, rather
than due to intrinsic stem-cell properties [32]. The other
type includes the fluorescence activated cell sorting
(FACS) and the magnetic activated cell sorting (MACS),
which are based on cell surface markers. The proposed
markers for liver CSCs include CD133, CD90, CD44,
CD13, EpCAM and OV6, on the basis of the hypothesis
that CSCs are originated from somatic stem cells and
Figure 3 Sphere-forming cells exhibited high tumorigenicity in vivo.( A )T h er e p r e s e n t a t i v ee x a m p l e so fx e n o g r a f tt u m o r sf o r m e da f t e r
subcutaneous injection with the PLC/PRF/5 parental cells and sphere-forming cells. (B) The top row shows the nodules formed by injecting 2 × 10
5,
5×1 0
5 and 1 × 10
6 PLC/PRF/5 parental cells, separately. The bottom row shows the nodules formed by injecting 5 × 10
2,1×1 0




4 and 5 × 10
4 PLC/PRF/5 sphere-forming cells, separately. (C) H&E staining revealed that the histological features of xenograft tumors induced by
the PLC/PRF/5 sphere-forming cells were similar to those induced by the parental cells.
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Although they have been reported to be used to enrich
CSC fraction, their sensitivity and specificity for identify-
ing liver CSCs are being challenged. For example, Kimura
et al reported CD133
+ fraction in Hep3B and Huh7 were
16.8% and 2.7%, respectively [7], whereas some other
groups reported more than 90% in Hep3B and 60% in
Huh7 [5,6]. In Huh7 the CD13-positive cells typically
existed in a CD133
strong fraction, but in PLC/PRF/5 the
CD13-positive cells were CD133-negative [9]. Some
researchers indicated that different culture conditions
and differentiated degree of the cells, especially the latter,
were important factors. The roles of these phenotypes in
defining functionally distinct populations of cells from
progenitor to differentiated hepatocytes need to be sys-
temically studied.
Recently, sphere culture has been increasingly used as
a method for enriching stem cells which relies on their
property of anchorage independent growth. Researchers
have reported the application of sphere culture to iso-
late, enrich, maintain or expand potential CSC subpopu-
lations from various types of cancers [18-25]. The
sphere-forming cells from primary tumors, such as
breast cancer and ovarian cancer, showed stem-like
properties and expressed their CSC markers [19,23]. It
is generally agreed that, like all stem cells, the tumor
sphere-forming cells are capable of proliferation, self-
renewal and possess higher tumorigenicity. Using neural
crest stem cell conditions and sphere formation system,
Hansford et al [35] for the first time successfully
expanded tumor cells both from low-risk neuroblasto-
mas and from the bone marrow metastases of high-risk
tumors. The latter formed metastatic tumors in a mur-
ine xenograft model with as few as 10 cells and could
also be serially passaged [35]. To our knowledge, there
have been few reports on the isolation and long-term
propagation of liver CSCs by the method of sphere
culture.
Figure 4 Sphere-forming cells overexpressed liver CSC related proteins and downstream proteins of the CSL-independent Notch
pathway. (A) The PLC/PRF/5 sphere-forming cells expressed the hepatic stem cell maker OV6, as observed under fluorescence microscopy.
Nuclei were stained with DAPI (400×). (B) Western blotting assay showed the liver CSC related proteins (Oct3/4, OV6, EpCAM, CD133 and CD44)
and the relative band intensities were calculated by densitometry and normalized to the loading control GAPDH.
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system, we tested three human hepatoma cell lines, PLC/
PRF/5, MHCC97H and HepG2. Cells are plated at a low
density (< 5000 cells/well in 6-well plate) to avoid sponta-
neous cell aggregation. The three cell lines could form clo-
nal nonadherent 3-D spheres, and without exceptions,
could also be serially passaged. We evaluated the PLC/
PRF/5 sphere-forming cells for their stemness characteris-
tics. It has been showed that they were capable of self-
renewal, proliferation, drug resistance, and overexpressing
liver CSC related proteins. Xenotransplantation is the gold
standard for evaluating tumorigenicity of tumor cells. We
tested the third, sixth and ninth generations of the PLC/
PRF/5 sphere-forming cells for their tumor initiating cap-
ability. It was demonstrated that as few as 500 cells from
the PLC/PRF/5 spheres were able to form a tumor when
subcutaneously injected into NOD/SCID mice, while 2 ×
10
5 parental cells were needed. This was 400 times higher
than that of sphere-forming cells. Moreover, the tumor
initiating capability was not decreased as the spheres were
passaged. Similar CSC properties of self-renewal, strongly
proliferation, drug resistance and tumorigenicity are also
found in the MHCC97H and HepG2 spheres. Indeed, the
HepG2 parental cells at 10
6 cells/mouse could not form
Figure 5 CSL-independent Notch signaling pathway might play a role in liver CSCs and MRK003 could partly eliminate the stem-like
cells. (A) The downstream proteins levels of the CSL-independent Notch pathway (DTX1 and Ep300) were significantly increased in the PLC/
PRF/5 spheres, compared with the parental cell line. GAPDH was used as a loading control. (B) 10 μM MRK003 could reduce the activation of
Notch1 and downstream components of CSL-independent Notch signaling pathway DTX1 and Ep300 were consequently decreased. (C) The
secondary dissociated PLC/PRF/5 sphere-forming cells were treated with 10 μM MRK003 or DMSO control for 7 days. The sphere formation
ability of the MRK003-treated groups were significantly inhibited in comparison to DMSO-treated controls.
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cells at the same amount of cells could form xenograft
tumors, suggesting the tumorigenic efficacies of sphere-
forming cells were enhanced compared with the parental
cancer cells.
To further explore the CSC properties of sphere-form-
ing cells, we examined the sensitivity of sphere-forming
cells to chemotherapeutics and the expression of candidate
CSC markers. The PLC/PRF/5 sphere-forming cells exhib-
ited general resistance to cisplatin, 5-Fu, gemcitabine,
mitomycin and sorafenib, and showed higher survival per-
centages compared with its parental cells. Synchronously,
we found that CD44 expression was obviously enriched in
HepG2 and MHCC97H sphere-forming cells compared
with their parental cells. CD44 is a polymorphic family of
immunologically related cell surface proteoglycans and
glycoproteins, normally takes part in cell-cell and cell-
matrix adhesion interactions, which is involved in cancer
cell migration, proliferation and metastasis. Accordingly,
CD44 expression enrichment in sphere-forming cells may
account for their increased survival ability and tumorigeni-
city. Therefore, we propose that the nonadherent tumor
spheres cultured in serum-free condition possess liver
CSC properties. This long-term culture system may also
provide the means of further purifying and functionally
characterizing the biological properties of the liver CSC
fraction, with the goal of developing new therapeutic stra-
tegies directed specifically against liver CSCs.
Accumulating evidence has been established that the
Notch signaling pathway plays vital and universal roles not
only in cell differentiation, embryonic development and
tissue self-renewal, but also in pathogenesis of some types
of human cancers and genetic disorders. Recent advance-
ments have further revealed that the Notch signals pro-
duce a marked effect either in stem cells or CSCs. The
activated Notch signals can inhibit hematopoietic stem
cell differentiation and maintain their pluripotency [36,37],
and maintaining the stem cell population in several solid
tissue types, including several neuroectodermal tissues
[38]. Only when the Notch signals are activated the cancer
stem cell activity could be enhanced to promote intestinal
tumor formation [39]. Generally, the Notch signaling path-
way is mediated in two different pathways. One is through
CSL-DNA binding proteins; the other is the CSL-indepen-
dent pathway. DTX1 (Deltex-1) is an important transcrip-
tional regulator that is downstream of the Notch receptor
in the CSL-independent Notch signaling pathway [40].
Ep300, also known as p300, is a transcriptional co-activa-
tor protein. It functions as a histone acetyltransferase that
regulates transcription via chromatin remodeling and is
important in the processes of cell proliferation and differ-
entiation. It has been reported that Ep300 can work as a
transcriptional co-activator of DTX1. Yamamoto et al [41]
reported that DTX1 inhibited the transcriptional
activation of the neural-specific helix-loop-helix type tran-
scription factor MASH1 by binding to Ep300. This
mechanism is likely responsible for the differentiation
inhibition of neural progenitor cells. In our study, the
result of stem cell microarrays showed that DTX1 and
Ep300 were highly expressed in liver cancer stem-like
cells. This was further confirmed by Western blotting.
Although the molecular mechanism and function of the
CSL-independent Notch signaling pathway have not been
elucidated, and little has been known about its involve-
ment in HCC, we suppose that the CSL-independent
Notch signaling pathway play an important role in the dif-
ferentiation and propagation of liver CSCs.
Conclusions
In summary, the study demonstrated that the nonadher-
ent tumor spheres from human hepatoma cell lines
which are cultured in stem cell conditioned medium
possess liver cancer stem cell properties, and the CSL-
independent Notch signaling pathway may play a role in
the differentiation and propagation of liver CSCs.
Additional material
Additional file 1: Figure S1. Tumorigenic efficacies of the hepatoma
sphere-forming cells. The hepatoma parental cells and sphere-forming
cells were injected into nude mice subcutaneously at the indicated cell
concentrations. At day 30
th after injection, mice were sacrificed and
tumors were removed and compared in size.
Additional file 2: Figure S2. Expression of candidate CSC markers in
hepatoma sphere-forming cells. Confocal immunofluorescent staining
showed that CD44 expression was enriched obviously in HepG2 and
MHCC97H sphere-forming cells compared with their parental cells. Nuclei
were stained with DAPI (400×).
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